Usa Financial Portformulas Corp Neurocrine Biosciences Inc Transaction History

Usa Financial Portformulas Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 12, 2024	SELL	$130.86 - $143.19 $11,384 - $12,457	-87 Reduced 26.36%	243 $33,000
Q1 2024 Apr 30, 2024	BUY	$130.4 - $143.74 $43,032 - $47,434	330 New	330 $45,000
Q2 2023 Nov 27, 2023	SELL	$89.53 - $104.87 $447 - $524	-5 Closed	0 $0
Q1 2023 Nov 27, 2023	BUY	$94.11 - $123.02 $470 - $615	5 New	5 $0
Q1 2018 Apr 03, 2018	SELL	$75.88 - $92.43 $494,054 - $601,811	-6,511 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$58.53 - $77.59 $381,088 - $505,188	6,511	6,511 $505,000

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Usa Financial Portformulas Corp, based on Form 13F filings with the SEC.

Stay updated on Usa Financial Portformulas Corp with notifications on news.